老年局部晚期食管鳞癌新辅助免疫化疗联合或不联合放疗的围术期结局比较
本研究回顾性纳入257例接受新辅助免疫化疗(194例)或新辅助免疫放化疗(63例)后行根治性食管切除术的老年(≥65岁)局部晚期食管鳞癌患者,采用倾向性评分逆概率加权平衡混杂因素。两组肺部并发症、吻合口并发症、住院时间及院内死亡率无显著差异。
要点
- 新辅助免疫放化疗增加手术时间、出血量、输血需求及心脏并发症风险。
- 两组肺部并发症、吻合口并发症、住院时间和院内死亡率无显著差异。
核心结论
- 对于老年局部晚期食管鳞癌患者,新辅助免疫放化疗相比新辅助免疫化疗提供更优的病理降期,但增加手术复杂性和心脏并发症风险。
研究设计与样本
- 回顾性队列研究,纳入2021年1月至2025年4月在四川省肿瘤医院接受新辅助免疫化疗(n=194)或新辅助免疫放化疗(n=63)后行根治性食管切除术的257例老年(≥65岁)局部晚期食管鳞癌患者,采用倾向性评分逆概率加权平衡混杂因素,并进行熵平衡加权和倾向性评分匹配的敏感性分析。
主要发现
- 新辅助免疫放化疗组术中出血量中位数210 mL(140-250 mL),新辅助免疫化疗组为170 mL(100-220 mL)。
临床怎么用
- 对于老年局部晚期食管鳞癌患者,选择新辅助免疫放化疗需权衡更高的病理缓解与增加的心脏并发症风险,支持个体化治疗决策。
局限性
- 本研究为单中心回顾性队列研究,样本量有限,尤其新辅助免疫放化疗组仅63例,可能存在残余混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Esophageal squamous cell carcinoma is a leading cause of cancer-related mortality, with elderly patients (≥65 years) representing a growing but underserved population because of limited evidence on neoadjuvant immunotherapy regimens. The choice between neoadjuvant immunochemotherapy and neoadjuvant immunochemoradiotherapy remains unresolved in this vulnerable group. METHOD: This retrospective cohort study included 257 elderly patients with locally advanced esophageal squamous cell carcinoma who underwent neoadjuvant immunochemotherapy (n = 194) or neoadjuvant immunochemoradiotherapy (n = 63), followed by radical esophagectomy at Sichuan Cancer Hospital between January 2021 and April 2025. The propensity score-based inverse probability weighting method was used to balance confounding factors. Perioperative outcomes were compared. Sensitivity analysis using entropy balancing weighting and propensity score matching was performed. RESULTS: The study revealed that compared with neoadjuvant immunochemotherapy , neoadjuvant immunochemoradiotherapy achieved a higher pathologic complete response rate (16% vs 41.3%; P < .001), whereas neoadjuvant immunochemoradiotherapy was associated with prolonged surgical duration (median, interquartile range, 3.8 h, 3.0 h-4.7 h vs 4.5 h, 4.0 h-5.0 h; P < .001), increased intraoperative blood loss (170 mL, 100-220 mL vs 210 mL, 140 mL-250 mL), higher blood transfusion requirements (3.6% vs 12.7%, P = .007), and elevated risks of cardiac complications (odds ratio, 3.21; 95% confidence interval, 1.34-7.69; P = .009) and major cardiac complications (odds ratio, 6.59; 95% confidence interval, 1.75-24.73; P = .005). No significant differences were observed in terms of pulmonary complications, anastomotic complications, pneumonia, anastomotic leakage, hospital length of stay, or in-hospital mortality between the 2 groups (all P > .05). The results were consistent after inverse probability weighting adjustment and in the sensitivity analysis. CONCLUSION: For elderly patients with locally advanced esophageal squamous cell carcinoma, neoadjuvant immunochemoradiotherapy provides superior pathologic downstaging but is associated with increased surgical complexity and cardiac complication risks compared with neoadjuvant immunochemotherapy. These results support personalized treatment decision-making to balance local tumor control and toxicity.
引用
- Tang X, Li Q, Wang Y, et al. Perioperative outcomes of neoadjuvant immunochemoradiotherapy versus immunochemotherapy followed by surgery in elderly patients with locally advanced esophageal squamous cell carcinoma. Surgery. 2026. PMID: 42385381. doi:10.1016/j.surg.2026.110379
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。